Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Xiamen University

Status and phase: Enrolling; Phase 2

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Treatments: Drug: venetoclax, chidamide, and chiglitazar sodium (VCC)

Study type: Interventional

Funder types: Other

Identifiers

NCT07783100

20260820VCC

Details and patient eligibility

About

To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).

Full description

This is a multicenter, prospective, single-arm clinical study evaluating the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML). Participants will receive VCC combination therapy according to the study protocol. The primary objective is to evaluate the antileukemic efficacy of the VCC regimen, while safety and tolerability will also be assessed throughout the study.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically confirmed acute myeloid leukemia (AML) with relapsed or refractory disease, including:

   • Refractory AML, defined as failure to achieve remission after at least one prior treatment;
   • Relapsed AML, defined as ≥5% blasts in the bone marrow after a previous remission;
   • AML arising from myelodysplastic syndrome (including CMML) or myeloproliferative neoplasms (secondary AML or therapy-related AML [t-AML]) is also eligible.

2. Age ≥18 years, regardless of sex, with an expected survival of >3 months.

3. Estimated creatinine clearance ≥50 mL/min.

4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × the upper limit of normal (ULN), unless the abnormality is considered attributable to leukemic organ involvement; total bilirubin ≤3.0 × ULN, unless the abnormality is considered attributable to leukemic organ involvement.

5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

6. Participants must not be pregnant and must agree to use effective contraception during study treatment.

7. Ability to understand the study and willingness to provide written informed consent.

Exclusion criteria

1. Acute promyelocytic leukemia (APL).

2. Active central nervous system leukemia.

3. Clinically significant cardiovascular disease, including any of the following:

   • Clinically significant QTc prolongation (QTc >450 ms in males or >470 ms in females);
   • Ventricular tachycardia;
   • Second-degree atrioventricular block;
   • Myocardial infarction within 1 year prior to enrollment;
   • Congestive heart failure;
   • Coronary artery disease requiring medical treatment.

4. Active, uncontrolled severe infection.

5. Other non-hematologic malignancies within the previous 2 years.

6. Psychiatric disorders that may interfere with participation in the study.

7. Previous solid organ transplantation. Prior stem cell transplantation (SCT) is permitted; however, patients with graft-versus-host disease (GVHD) or those receiving ongoing immunosuppressive or GVHD-directed therapy are not eligible.

8. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

VCC

Experimental group

Description:

Chidamide, venetoclax, chiglitazar sodium.

Treatment:

Drug: venetoclax, chidamide, and chiglitazar sodium (VCC)